Merus Announces Abstracts Accepted for Presentation at the 2024 ASCO Annual Meeting
Petosemtamab in combination with pembrolizumab in 1L HNSCC initial interim clinical data selected for rapid oral session presentation
MCLA-145 as monotherapy or in combination with pembrolizumab in solid tumors initial interim clinical data selected for rapid oral session presentation
MCLA-129 in NSCLC with c-MET exon 14 skipping mutations initial interim clinical data selected for poster presentation
UTRECHT, The Netherlands and CAMBRIDGE, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics and Triclonics), today announced the acceptance of three abstracts for presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, being held in Chicago, Illinois on May 31- June 4, 2024.
Rapid oral presentation:
Title: Petosemtamab (MCLA-158) with pembrolizumab as first-line (1L) treatment of recurrent/metastatic (r/m) head and neck squamous cell carcinoma (HNSCC): Phase 2 study
Abstract #: 6014
Session Title: Head and Neck Cancer
Session Date and Time: June 3, 2024, 8:00-9:30 a.m. CT
The presentation concerns petosemtamab evaluated in combination with pembrolizumab in patients with untreated advanced PD-L1+ HNSCC.
Lesen Sie auch
Rapid oral presentation:
Title: Phase I study of MCLA-145, a bispecific antibody targeting CD137 and PD-L1, in solid tumors, as monotherapy or in combination with pembrolizumab
Abstract #: 2520
Session Title: Developmental Therapeutics—Immunotherapy
Session Date and Time: June 2, 2024, 11:30 a.m.-1:00 p.m. CT
The presentation concerns MCLA-145 evaluated as monotherapy or in combination with pembrolizumab in patients with solid tumors.
Poster presentation:
Title: Efficacy and safety of MCLA-129, an anti-EGFR/c-MET bispecific antibody, in non-small-cell lung cancer (NSCLC) with c-MET exon 14 skipping mutations (METex14)
Abstract #: 8583
Session Title: Lung Cancer—Non-Small Cell Metastatic
Session Date and Time: June 3, 2024, 1:30-4:30 p.m. CT
The presentation concerns MCLA-129 evaluated as monotherapy in patients with locally advanced/metastatic METex14 NSCLC.
The abstracts will be available on the ASCO website on May 23, 2024 at 5:00 p.m. ET. The full presentations will be available on the Merus website at the start of each session.
About Petosemtamab
Petosemtamab, or MCLA-158, is a bispecific Biclonics low-fucose human full-length IgG1 antibody targeting the epidermal growth factor receptor (EGFR) and the leucine-rich repeat containing
G-protein-coupled receptor 5 (LGR5). Petosemtamab is designed to exhibit three independent mechanisms of action including inhibition of EGFR-dependent signaling, LGR5 binding leading to EGFR
internalization and degradation in cancer cells, and enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP) activity.